Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company that pioneers personalized cell therapies for oncology and immunology indications. The company's research is centered on its sterically-optimized CAR-T cell therapy platform, which aims to treat severe conditions by genetically modifying immune cells. Its flagship product candidate, NXC-201, is a BCMA-targeted CAR-T therapy currently in clinical trials for relapsed/refractory AL Amyloidosis and multiple myeloma. Additionally, Immix Biopharma is advancing IMX-110, a tissue-specific therapeutic for solid tumors such as soft tissue sarcoma. Headquartered in Los Angeles, California, the company conducts its clinical operations across multiple sites in the United States and Australia.
